Innovative Drugs
China-Originated Targeted Drugs
FDA / NMPA / EMA approved
Typical Duration
Long-term oral/IV therapy; initial assessment 1–2 weeks
Estimated Cost
Many NRDL-listed; self-pay far below overseas
Most targeted agents approved in China are on the National Reimbursement Drug List or have patient-assistance programs; international patients self-pay, yet originator prices are generally well below US/EU levels. Exact prices follow hospital pharmacy rates.
Why China
China-Originated Targeted Drugs
01China-originated targeted drugs go global
Zanubrutinib became the first China-originated cancer drug approved by the FDA and leads the global BTK market; fruquintinib and ivonescimab followed with Western approvals or head-to-head wins over international blockbusters.
02Deep driver-genomics expertise
Chinese teams have led pivotal global studies across EGFR, ALK, ROS1, KRAS G12C, MET and RET targets, and possess unique expertise in mutation spectra specific to Asian populations, such as high EGFR-mutation rates in lung cancer.
03World-leading speed of new-drug access
NMPA accelerated review keeps narrowing the launch gap for global drugs in China, with some agents (such as ivonescimab) approved first in China; the Boao Lecheng pilot zone additionally permits special access to drugs approved overseas but not yet in mainland China.
04Comprehensive genomic-testing infrastructure
Major centers routinely run large NGS panels with 7–10 working-day turnaround, and integrated pathology-molecular-clinical tumor boards (MTB) translate results directly into treatment plans.
Care Journey
01
Case Review
Submit your records and imaging; receive a written expert assessment and preliminary plan within 48 hours.
02
Plan & Estimate
A multidisciplinary team (MDT) defines your individualized treatment plan with a transparent cost estimate.
03
Travel Preparation
We assist with medical visa, flights and accommodation, and assign a professional medical interpreter.
04
In-Hospital Care
A dedicated coordinator accompanies you through examinations and treatment, bridging all communication.
05
Recovery & Follow-up
Remote follow-up after you return home, with review schedules and medication guidance.
06
Long-term Management
Stay connected with your treating team, with fast-track return visits whenever needed.
Medical Team
Hospitals
Cancer Hospital, CAMS (National Cancer Center)
Beijing · Grade III-A · National Cancer Center
Fudan University Shanghai Cancer Center
Shanghai · Grade III-A · National Regional Cancer Center
Sun Yat-sen University Cancer Center
Guangzhou · Grade III-A · Host of State Key Laboratory
Peking University Cancer Hospital
Beijing · Grade III-A · MOE Key Laboratory
Frequently Asked Questions
Can I start targeted therapy without genetic testing?+
Not recommended. With few exceptions, targeted therapy must be based on pathological confirmation and molecular testing (EGFR/ALK/KRAS/HER2 etc.). If re-biopsy or testing is needed, major centers can quickly arrange needle biopsy, effusion cytology or liquid biopsy.
Can I buy medication in China and take it home?+
Targeted therapy requires initiation assessment, dose titration and toxicity monitoring — “pick up and leave” is not advised. The proper pathway is on-site assessment and first dosing, a follow-up plan, then medication at home with remote reviews. Lecheng special-access drugs must be administered within Lecheng with required follow-up.
What happens after resistance develops?+
Major centers routinely perform re-biopsy and molecular testing at resistance, switching to next-generation agents, combinations or clinical studies based on the mechanism (e.g. MET-amplification testing and combination targeting after EGFR resistance). China’s active pipeline offers more later-line options.
Originator vs generics — how to choose?+
Chinese generics that have passed consistency evaluation are bioequivalent to originators at substantially lower prices; in some scenarios (combinations, special formulations) originators remain preferable. Physicians advise based on drug properties, availability and your budget; all medications we coordinate come through official hospital channels.
How severe are the side effects?+
Most targeted-agent toxicities are manageable (rash, diarrhea, transaminase elevation) with dose adjustment and supportive care; a few carry special risks such as interstitial lung disease or cardiac effects requiring baseline assessment and monitoring. Initial dosing is best done under observation with a follow-up plan.
Detailed Information
Testing first: NGS and molecular tumor boards
Proper targeted therapy starts with high-quality molecular testing. Major centers offer NGS panels covering hundreds of genes (tissue or liquid biopsy) with 7–10 working-day turnaround; complex results go to a molecular tumor board (MTB) where pathology, molecular diagnostics and clinical specialists interpret them together — avoiding both “mutation found but no drug available” and driver misclassification.
Representative China-originated targeted agents
The following are representative agents with global impact (see our Innovative Drugs page for the full list); suitability depends on genomic testing and physician assessment.
| Agent | Target | Indication focus | Significance |
|---|---|---|---|
| Zanubrutinib (Brukinsa) | BTK | CLL/SLL, Waldenström’s, MCL etc. | First China-originated cancer drug FDA-approved; beat ibrutinib head-to-head |
| Fruquintinib (Fruzaqla) | VEGFR 1/2/3 | Third-line+ metastatic colorectal cancer | Approved in the US, EU and Japan; a global later-line standard |
| Ivonescimab (Ivonescimab) | PD-1 × VEGF bispecific | EGFR-TKI resistant NSCLC etc. | Head-to-head superiority over pembrolizumab; first approved in China |
| Surufatinib (Sulanda) | VEGFR/FGFR/CSF-1R | Pancreatic and extra-pancreatic NET | First oral targeted agent covering NET of all origins |
Therapy management and post-resistance strategy
After starting targeted therapy, imaging response is assessed at 4–8 weeks and then every 2–3 months; dose adjustments, intermittent schedules and supportive care are managed by the treating team. At progression, re-biopsy and molecular testing clarify the resistance mechanism, guiding next-generation agents (e.g. EGFR C797S, MET amplification, HER2 bypass), combinations or clinical studies.
Boao Lecheng special-access pathway
The Boao Lecheng International Medical Tourism Pilot Zone operates under a national special policy: drugs and devices approved overseas but not yet in mainland China may be used under license. The process: treating physician assessment and application → regulatory approval (usually a few working days) → bonded import → in-zone administration with required follow-up. It suits patients who urgently need a specific overseas drug with no domestic alternative.
Check whether my case is eligible
Book a Consultation